Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues

Blueprint Medicines (BPMC) PT Raised to $98 at Wedbush

February 22, 2018 3:28 PM EST

Wedbush raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $98.00 (from $96.00) while maintaining a Outperform rating.

Analyst David Nierengarten commented, "In addition to working toward enrollment of the registration-directed PDGFR-driven GIST trial set to complete mid-year, BPMC has moved... More